In general, treatments were most successful when Vγ9Vδ2 cells were expanded ex vivo prior to injection, when cell treatments coincided with tumor cell implantation or occurred when tumors were first deemed “palpable” (meaning < 100 mm3 volume) and required repeated administration of phosphoantigen or aminobisphosphonate drugs plus cytokine (usually IL-2). The gene discussed is IL2; the disease is neoplasm.